Legal and regulatory exposuremixed · 4 filings
“The increase in other research and development expenses of $0.4 million was primarily due to consulting and regulatory expenditures incurred for non-specific programs.”10-Q · May 7, 2026 ↗
Climb Bio, Inc.
CLYM
Market read
Climb Bio, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 11 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 13 directly disclosed connections are confirming.
Company-4.7% todayVolume comparison unavailable
Market group0 of 11 activeBiotech and Gold · unavailable
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
Watch this read- CLYM's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if CLYM's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 11 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 13 directly disclosed connections are confirming.
Evidence that supports
No thresholded supportive filing evidence is available yet.
Evidence that challenges
No thresholded adverse filing evidence is available yet.
What would clarify the read
- CLYM's market-adjusted activity becomes unusual and at least one connected name confirms.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods0
Price observations320
Usable filing statements52
Verified relationships12
Evidence supporting the case
- Macroeconomic conditions has repeated favorable evidence across 3 filings.
- Tariffs and trade policy has repeated favorable evidence across 3 filings.
Evidence challenging the case
No qualifying adverse evidence was identified; that is not proof there is no downside.
Questions before a position
No credible peer-relative valuation comparison is available yet.
Longer-term price context
Price as of Sep 11, 2026
14.276m+101.8%12m+520.2%24m—
What management says matters
Persistent and emerging business drivers
Capital investment and capacitymixed · 3 filings
“For example, in August 2011, the Budget Control Act of 2011 was signed into law, which, among other things, included aggregate reductions to Medicare payments to providers of, on average, 2% per fiscal year, effective April 1, 2013, which, due to subsequent l…”10-Q · May 7, 2026 ↗
Macroeconomic conditionspositive · 3 filings
“Prior to the recent imposing of tariffs on China, trade tensions and conflicts between the U.S.”10-Q · May 7, 2026 ↗
Tariffs and trade policypositive · 3 filings
“Prior to the recent imposing of tariffs on China, trade tensions and conflicts between the U.S.”10-Q · May 7, 2026 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales — · EV/sales —. Comparisons use only industry-matched filing peers.
Scenario scaffold
Fewer than 4 annual revenue periods; too little history to scaffold scenarios.
Price action
How the market is pricing the story
14.27-4.7% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for CLYM. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for CLYM. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind CLYM
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
Depended on by
JBIOJade Biosciences, Inc.competitorMay 7, 2026 ▾
“We compete with a variety of multinational biopharmaceutical companies, specialized biotechnology companies and emerging biotechnology companies, including Biogen Inc., Biohaven, Ltd., Calliditas Therapeutics AB, Climb Bio, Inc., Novartis AG, Otsuka Pharmaceu…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 12 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
CLYM is currently a Follower in the organic co-movement group Biotech and Gold. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for CLYM; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.